Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study von Vermeij, Renee, Leffers, Ninke, Hoogeboom, Baukje-Nynke, Hamming, Ineke L.E., Wolf, Rinze, Reyners, Anna K.L., Molmans, Barbara H.W., Hollema, Harry, Bart, Joost, Drijfhout, Jan W., Oostendorp, Jaap, van der Zee, Ate G.J., Melief, Cornelis J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

Volltext

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response von van Poelgeest, Mariëtte I E, Welters, Marij J P, Vermeij, Renee, Stynenbosch, Linda F M, Loof, Nikki M, Berends-van der Meer, Dorien M A, Löwik, Margriet J G, Hamming, Ineke L E, van Esch, Edith M G, Hellebrekers, Bart W J, van Beurden, Marc, Schreuder, Henk W, Kagie, Marjolein J, Trimbos, J Baptist M Z, Fathers, Lorraine M, Daemen, Toos, Hollema, Harry, Valentijn, A Rob P M, Oostendorp, Jaap, Oude Elberink, J Hanneke N G, Fleuren, Gertjan J, Bosse, Tjalling, Kenter, Gemma G, Stijnen, Theo, Nijman, Hans W, Melief, Cornelis J M, van der Burg, Sjoerd H

Volltext

Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial von Leffers, Ninke, Lambeck, Annechien J.A., Gooden, Marloes J.M., Hoogeboom, Baukje‐Nynke, Wolf, Rinze, Hamming, Ineke E., Hepkema, Bouke G., Willemse, Pax H.B., Molmans, Barbara H.W., Hollema, Harry, Drijfhout, Jan W., Sluiter, Willem J., Valentijn, A. Rob P.M., Fathers, Loraine M., Oostendorp, Jaap, van der Zee, Ate G.J., Melief, Cornelis J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

Volltext

Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer von Leffers, Ninke, Vermeij, Renee, Hoogeboom, Baukje-Nynke, Schulze, Ute R., Wolf, Rinze, Hamming, Ineke E., van der Zee, Ate G., Melief, Kees J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

Volltext

Distinct regulation and impact of type 1 T‐cell immunity against HPV16 L1, E2 and E6 antigens during HPV16‐induced cervical infection and neoplasia von van Poelgeest, Mariëtte I.E., Nijhuis, Esther R., Kwappenberg, Kitty M.C., Hamming, Ineke E., Wouter Drijfhout, Jan, Fleuren, Gert Jan, van der Zee, Ate G.J., Melief, Cornelis J.M., Kenter, Gemma G., Nijman, Hans W., Offringa, Rienk, van der Burg, Sjoerd H.

Volltext